Tislelizumab
- Generic Name
- Tislelizumab
- Brand Names
- Tevimbra, Tizveni
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1858168-59-8
- Unique Ingredient Identifier
- 0KVO411B3N
- Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
- Indication
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。
⑵用于治疗局部晚期或转移性尿路上皮癌。
⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。
⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。
⑸用于治疗晚期恶性实体瘤
- Associated Conditions
- -
- Associated Therapies
- -
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 344
- Registration Number
- NCT04699188
- Locations
- 🇺🇸
Emory University School of Medicine-Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Providence Cancer Center, Portland, Oregon, United States
AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 178
- Registration Number
- NCT04693234
- Locations
- 🇨🇳
Mackay Memorial Hospital, Taipei, Taiwan
🇧🇬Medical center nadezhda clinical eood, Sofia, Bulgaria
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 16
- Registration Number
- NCT04672330
- Locations
- 🇨🇳
Shanghai Renji Hospital, Shanghai, Shanghai, China
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- PureTech
- Target Recruit Count
- 80
- Registration Number
- NCT04666688
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
🇺🇸University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States
Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC
- Conditions
- Interventions
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- Ming Zhao
- Target Recruit Count
- 120
- Registration Number
- NCT04663035
- Locations
- 🇨🇳
Department of Minimally Invasive and Interventional Radiology, Liver Cancer Study and Service Group, Sun Yat-sen University Cancer Center,, Guangzhou, Guangdong, China
BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 330
- Registration Number
- NCT04649385
- Locations
- 🇺🇸
Icahn School of Medicine At Mount Sinai, New York, New York, United States
🇦🇺Ashford Cancer Centre Research Northeast, Windsor Gardens, South Australia, Australia
🇦🇺Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
- Conditions
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 600
- Registration Number
- NCT04627012
- Locations
- 🇨🇳
Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT04620837
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC
- Conditions
- Interventions
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 80
- Registration Number
- NCT04615143
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Hutchison Medipharma Limited
- Target Recruit Count
- 112
- Registration Number
- NCT04577963
- Locations
- 🇺🇸
Florida Cancer Specialists - FCS South, Port Charlotte, Florida, United States
🇺🇸Florida Cancer Specialists - East (FCS East), West Palm Beach, Florida, United States
🇺🇸Tennessee Oncology-Chattanooga, Chattanooga, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.